ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Roche (RHHBY) Smart-bomb Breast-Cancer Drug Slows Tumor Growth


6/4/2012 6:49:38 AM

An experimental antibody-drug conjugate therapy from the Genentech unit of Roche(RHHBY) delayed by more than three months the re-growth of breast cancer compared to the current standard of care, according to a phase III study being presented today at the American Society of Clinical Oncology (ASCO) annual meeting. The drug, known as T-DM1, will be filed for regulatory approval in the U.S. and Europe later this year, Roche said. T-DM1 is a second-generation version of Genentech's blockbuster breast cancer drug Herceptin. The drug consists of Herceptin (also known as trastuzumab) linked to a tumor-killing chemotherapy payload developed by ImmunoGen(IMGN_).

Read at The Street.com
Read at Fox News
Read at Oregon Live
Read at Reuters
Read at Wall Street Journal
Read at Bloomberg
 
 Read Article at  Related Companies  News Categories
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES